Novo Nordisk Launches First Once-Weekly Basal Insulin in U.S.
Event summary
- Novo Nordisk launched Awiqli®, the first once-weekly basal insulin for type 2 diabetes, in the U.S. on August 11, 2026.
- Awiqli® is available at over 70,000 pharmacies nationwide and eligible patients can pay as little as $35 per month through affordability programs.
- The FDA approval was based on results from the ONWARDS phase 3a clinical program, which demonstrated non-inferiority in mean change in HbA1c compared to daily basal insulin.
- Common adverse events include hypoglycemia, allergic reactions, and weight gain.
The big picture
Novo Nordisk's launch of Awiqli® represents a significant innovation in diabetes care, addressing the challenge of daily insulin injections. The once-weekly dosing could improve patient compliance and outcomes, potentially reshaping the basal insulin market. With over 70,000 pharmacies offering the product and affordability programs in place, Novo Nordisk is positioning Awiqli® as a key player in the type 2 diabetes treatment landscape.
What we're watching
- Market Adoption
- How quickly Awiqli® will be adopted by patients and healthcare providers, given its once-weekly dosing advantage.
- Competitive Response
- Whether competitors like Sanofi or Eli Lilly will accelerate development of their own once-weekly insulin products.
- Regulatory Scrutiny
- The pace at which regulatory bodies in other regions approve Awiqli®, expanding its global availability.
Related topics